vs
Side-by-side financial comparison of CITIUS ONCOLOGY, INC. (CTOR) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $3.9M, roughly 1.2× CITIUS ONCOLOGY, INC.). CITIUS ONCOLOGY, INC. runs the higher net margin — -140.3% vs -200.5%, a 60.1% gap on every dollar of revenue.
Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
CTOR vs MXCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.8M |
| Net Profit | $-5.5M | $-9.6M |
| Gross Margin | 80.0% | — |
| Operating Margin | -133.2% | -234.5% |
| Net Margin | -140.3% | -200.5% |
| Revenue YoY | — | -20.9% |
| Net Profit YoY | 16.9% | 9.4% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.8M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | — | $5.8M | ||
| Q1 25 | — | $5.7M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $5.0M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | $-5.5M | $-9.6M | ||
| Q3 25 | — | $-12.4M | ||
| Q2 25 | — | $-12.4M | ||
| Q1 25 | — | $-10.3M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | — | $-11.6M | ||
| Q2 24 | — | $-9.4M | ||
| Q1 24 | — | $-9.5M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -133.2% | -234.5% | ||
| Q3 25 | — | -307.4% | ||
| Q2 25 | — | -244.3% | ||
| Q1 25 | — | -214.1% | ||
| Q4 24 | — | -213.1% | ||
| Q3 24 | — | -250.4% | ||
| Q2 24 | — | -241.0% | ||
| Q1 24 | — | -219.8% |
| Q4 25 | -140.3% | -200.5% | ||
| Q3 25 | — | -269.7% | ||
| Q2 25 | — | -212.2% | ||
| Q1 25 | — | -178.7% | ||
| Q4 24 | — | -175.0% | ||
| Q3 24 | — | -205.9% | ||
| Q2 24 | — | -188.8% | ||
| Q1 24 | — | -170.6% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.4M | $171.5M |
| Total Assets | $110.0M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3M | $103.0M | ||
| Q3 25 | — | $105.7M | ||
| Q2 25 | — | $126.6M | ||
| Q1 25 | — | $138.3M | ||
| Q4 24 | — | $154.5M | ||
| Q3 24 | — | $153.8M | ||
| Q2 24 | — | $157.3M | ||
| Q1 24 | — | $157.5M |
| Q4 25 | $58.4M | $171.5M | ||
| Q3 25 | — | $180.3M | ||
| Q2 25 | — | $190.7M | ||
| Q1 25 | — | $199.4M | ||
| Q4 24 | — | $206.3M | ||
| Q3 24 | — | $213.3M | ||
| Q2 24 | — | $221.3M | ||
| Q1 24 | — | $226.4M |
| Q4 25 | $110.0M | $202.5M | ||
| Q3 25 | — | $213.5M | ||
| Q2 25 | — | $219.8M | ||
| Q1 25 | — | $230.0M | ||
| Q4 24 | — | $239.5M | ||
| Q3 24 | — | $248.6M | ||
| Q2 24 | — | $251.5M | ||
| Q1 24 | — | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.9M |
| FCF MarginFCF / Revenue | — | -61.0% |
| Capex IntensityCapex / Revenue | — | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.4M | $-2.7M | ||
| Q3 25 | — | $-7.5M | ||
| Q2 25 | — | $-9.9M | ||
| Q1 25 | — | $-14.4M | ||
| Q4 24 | — | $-7.8M | ||
| Q3 24 | — | $-4.4M | ||
| Q2 24 | — | $-4.8M | ||
| Q1 24 | — | $-10.6M |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $-7.8M | ||
| Q2 25 | — | $-10.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-11.4M |
| Q4 25 | — | -61.0% | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -179.2% | ||
| Q1 25 | — | -262.3% | ||
| Q4 24 | — | -131.6% | ||
| Q3 24 | — | -85.5% | ||
| Q2 24 | — | -103.3% | ||
| Q1 24 | — | -203.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 10.0% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 14.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTOR
Segment breakdown not available.
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
